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Purpose: Primary congenital glaucoma (PCG) is an autosomal recessive form of glaucoma that manifests within the first
year of life and if left untreated, leads to irreversible blindness. Cytochrome P450 1B1 (CYP1B1) is the major gene known
to be associated with PCG. The role of the CYP1B1 gene in disease pathogenesis and the relatively low detection rate of
CYP1B1 mutations in some populations, especially Asians, remain unexplained. We hypothesized that altered gene dosage
of CYP1B1 or anterior segmental dysgenesis causative genes may be involved in the pathogenesis of PCG.
Methods: We performed whole genome exon-focused array comparative genome hybridization (aCGH) to identify copy
number variation (CNV) in 20 Korean PCG patients and their parents.
Results: We identified 12 patients with at least one rare gene-containing copy number variation each, corresponding to
25 CNVs (5 deletions and 20 duplications) at frequencies of 5-30% in PCG patients and 0% in controls. The 25 CNVs
were not located at known chromosomal loci for PCG, namely GLC3A, which harbors CYP1B1 (2p21), GLC3B (1p36.2-
p36.1), or GLC3C (14q23), and did not include any target genes associated with PCG or anterior segmental dysgenesis.
Conclusions: Further genetic studies with larger cohorts of patients are necessary to validate our results and to elucidate
other genetic mechanisms underlying PCG, because the identified CNVs might be PCG-specific pathogenic variants and
may explain the disease pathogenesis of PCG.
Primary  congenital  glaucoma  (PCG),  an  autosomal
recessive disorder of the eye that usually manifests within the
first year of life, is caused by developmental defects in the
trabecular meshwork and anterior chamber angle [1]. These
developmental defects cause obstruction of aqueous outflow,
leading  to  increased  intraocular  pressure  and  optic  nerve
damage. If left untreated, PCG leads to irreversible blindness
[2].
Three  loci  for  PCG  (gene  symbol  GLC3),  namely
GLC3A  (chromosome  2p2-p21),  GLC3B  (chromosome
1p36.2-p36.1), and GLC3C (chromosome 14q23), have been
mapped by linkage analysis [3-5]. Cytochrome p450 1B1
(CYP1B1; OMIM 601771), which is associated with GLC3A,
is known to be the major gene associated with PCG. The
coding and promoter regions of CYP1B1 have been screened
extensively  in  PCG  patients  worldwide.  However,  the
pathway  by  which  CYP1B1  affects  development  of  the
anterior chamber of the eye remains unknown. In addition, the
prevalence  of  CYP1B1  mutations  varies  in  different
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populations,  ranging  from  ~10%  in  Mexico  to  100%  in
consanguineous Slovakian Gypsy patients. The incidence of
CYP1B1 gene involvement in Korean, Chinese, and Japanese
PCG patients is relatively low (~20%), which means that it is
not possible to explain the genetic pathogenesis of PCG in
more than half of patients who do not have any CYP1B1
mutations or only one mutant CYP1B1 allele [6-10]. To try to
explain  these  findings,  we  noted  that  anterior  segmental
dysgenesis  (ASD)  disorders  such  as  Axenfeld-Rieger
syndrome,  Peters’  anomaly,  and  iris  hypoplasia,  are
associated with raised intraocular pressure and an increased
incidence of glaucoma. Furthermore, the eye is exquisitely
sensitive  to  both  reduced  and  increased  doses  of  key
developmental  genes  such  as  paired  box  6  (PAX6)  and
forkhead box C1 (FOXC1), as demonstrated in ASD [11-15].
In this context, we expanded the disease spectrum of PCG
to ASD and hypothesized that identification of underlying
genomic imbalances could lead to elucidation of other genetic
mechanisms underlying PCG. Therefore, our aim in this study
was  to  explore  alternative  genetic  mechanisms  related  to
disease pathogenesis in PCG. We performed whole genome
exon-focused  array  CGH  (aCGH)  to  investigate  the  most
susceptible  copy  number  variations  (CNVs)  in  20  PCG
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3583patients and their parents. To the best of our knowledge, this
is the first gene dosage analysis of PCG patients using aCGH.
METHODS
Patients  and  clinical  evaluation:  Twenty  Korean  PCG
patients and their unaffected parents were recruited during a
multi-institutional collaborative study from September 2008
to February 2010 and included in this study. Clinical data
including CYP1B1 and myocillin (MYOC) sequencing results
of subjects with PCG are shown in Table 1. Criteria for PCG
diagnosis were evaluated when examination was possible and
included IOP ≥21 mmHg in at least one eye; megalocornea;
corneal  edema/clouding/opacity;  and  glaucomatous  optic
nerve  head  damage.  Corroborating  features  included
symptoms of epiphora and photophobia. Patients with other
ocular or systemic anomalies were excluded. Of the 20 PCG
patients,  only  two  patients  had  a  known  heterozygous
mutation  and  a  novel  mutation  in  CYP1B1  and  MYOC,
respectively.
Array CGH analysis: To identify highly susceptible CNVs in
PCG compared with control individuals, we performed aCGH
on 20 PCG patients and their parents along with 99 healthy
individuals. Genomic DNA was extracted from peripheral
blood leukocytes using a Wizard Genomic DNA Purification
kit according to the manufacturer’s instructions (Promega,
Madison, WI). A total of 159 DNA samples were labeled and
co-hybridized to determine DNA copy number changes in
deletion/duplication  using  the  NimbleGen  Human  CGH
3x720K  Whole  Genome  Exon-Focused  Array  (Roche
Diagnostics, Mannheim, Germany). Arrays were washed and
then scanned using a NimbleGen MS 200 Microarray Scanner
with 2 µm scanning resolution. Raw copy number data were
normalized using Nexus software 5.0 (Nexus BioDiscovery,
El Segundo, CA). All probe coordinates were mapped to the
National  Center  for  Biotechnology  Information  (NCBI)
human  genome  assembly  Build  36  (UCSC  hg18).  The
normalized data were then processed with quality controls
using Nexus Software and the manufacturer’s recommended
default settings. To remove wave artifacts, we checked the
number of aligned probes with signal quality and applied
lowess correction to the log2 ratios. The same CNV types were
merged with adjacent CNV calls using the criteria of ≤10
probes and ≤50 kb apart. The data were loaded into the Fast
Adaptive  States  Segmentation  Technique  (FASST)
segmentation  algorithm  with  a  significance  threshold  of
1.0×10−5. To minimize the number of false positive CNV calls
without  compromising  the  sensitivity  of  detection  of  true
CNVs, we applied log2 ratios with thresholds of 0.3 in gain
signals and −0.5 in loss signals. We visually inspected each
sample, and excluded CNVs with <5 probes or CNVs ≤500
bp in length.
Identification of copy number variations: The CNV filtering
strategy that we used is summarized in Figure 1. To describe
the  candidate  CNVs,  we  used  the  Database  of  Genomic
Variants (DGV; The Centre for Applied Genomics, Toronto,
Canada)  to  determine  whether  the  CNVs  were  novel  or
known.  We  excluded  known  CNVs  in  DGV  and  those
identified in controls, and determined candidate genes using
the identified CNVs.
TABLE 1. CLINICAL DATA INCLUDING CYP1B1 AND MYOC SEQUENCING RESULTS OF SUBJECTS WITH PRIMARY CONGENITAL GLAUCOMA.
Individual
number
Gender Age of onset
(months)
Affected
eye(s)
IOP at diagnosis
(OD;OS)
Family
history
CYP1B1 mutation MYOC mutation
1 M 10 U 22 - - -
2 M 3 B 22/16 - - -
3 M 76 B 30/24 Sibling - -
4 F 21 B 34/17 - - -
5 F <1 B 30/32 - - -
6 M 29 U 34 - - L228S
(heterozygote)
7 F <1 U 23 - - -
8 F <1 U 22.4 - - -
9 F 117 B 11/44 - - -
10 M 5 U 33/15 - - -
11 F 3 U 28 - - -
12 F 1 U 18.5 - - -
13 F 35 U 30 - - -
14 F 10 B 52/52 - - -
15 F 5 U 28 - - -
16 M 6 U 22.5 - -
17 M 4 B 37/35 - A330F
(heterozygote)
-
18 M 2 B 26/32 - - -
19 M 10 U 18.5 - - -
20 F 1 B 21/30 - - -
Abbreviation: U, unilateral; B, bilateral.
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3584Figure 1. Summary of the copy number variation filtering strategy used in this study.
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3585We then matched the candidate genes detected in PCG
patients against their parents’ CNVs to analyze the mode of
inheritance. The identified CNVs were classified according to
type  (Figure  1)  and  we  evaluated  whether  they  were
responsible for the disease phenotype of the patients or not.
To narrow down the potential candidate CNVs (genes)
and match the identified CNVs to target regions and/or genes,
we first focused on known chromosomal loci for PCG, namely
GLC3A (2p2-p21), which harbors CYP1B1, GLC3B (1p36.2-
p36.1), and GLC3C (14q23). Second, candidate genes with
identified  CNVs  were  matched  against  both  PCG-related
genes and ASD causative genes including CYP1B1, MYOC,
latent  transforming  growth  factor-beta  binding  protein  2
(LTBP2),  PAX6,  paired-like  homeodomain  transcription
factor  2  (PITX2),  PITX3,  FOXC1,  forkhead  box  E3
(FOXE3), eyes absent 1 (EYA1), LIM homeobox transcription
factor 1 beta (LMX1B), and v-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog (MAF) [11,16-18].
We next identified highly predicted functional partners
of the target genes listed above using the Search Tool for
Retrieval of Interacting Genes/Proteins database (STRING,
version 8.3), and we determined if any CNVs were associated
with these genes (Table 2). The STRING database comprises
known and predicted protein interactions, including direct
(physical)  and  indirect  (functional)  associations;  these
interactions  are  derived  based  on  genomic  context,  high-
throughput  experiments,  conserved  co-expression,  and
previous knowledge. An example of the STRING 8.3 results
for CYP1B1 is provided in Figure 2.
RESULTS
We performed aCGH to detect rare CNVs in PCG patients that
were not present in 99 healthy controls. We identified 12
patients with at least one rare gene-containing deletion or
duplication, corresponding to 25 CNVs (5 deletions and 20
duplications) at frequencies of 5%–30% in PCG patients and
0% in the controls (Table 3). According to the literature, most
CNVs  have  a  Mendelian  inheritance  pattern  [19,20].
Therefore, we performed aCGH using parent-offspring trios,
because  the  use  of  family  information  can  improve  the
sensitivity and specificity of CNV detection. We matched 25
CNVs against the parents’ CNVs, which were classified into
three main categories: loss of 1 copy from one parent (5
CNVs), gain of 1 copy from one parent (9 CNVs), and gain
of 1 copy from de novo variation (6 CNVs). The remaining 5
CNVs were classified as ‘other’. No CNV was transmitted in
an autosomal recessive inheritance manner. Considering that
both parents of all patients were unaffected, loss or gain of
one copy from only one parent is not likely to be associated
with the disease phenotype. Only the gain of one copy due to
de novo variation may represent an autosomal dominant mode
of inheritance.
We found that the 25 CNVs, identified within 28 genes,
were not located in known chromosomal loci for PCG, namely
TABLE 2. TABLE OF PREDICTED FUNCTIONAL PARTNERS OF THE CYP1B1, MYOC, LTBP2, PAX6, PITX2, PITX3, FOXC1, FOXE3,
EYA1, LMX1B, AND MAF GENES BY STRING 8.3.
CYP1B1 MYOC LTBP2 PAX6 PITX2 PITX3
COMT OPTN LTB SIX3 CTNNB1 TH
GSTM1 CYP1B1 TGFBI MITF SUCLG1 SLC6A3
GSTP1 WDR36 ZNF185 SOX2 LEF1 GDNF
UGT1A1 SNCG ELN NEUROG2 FOXC1 NR4A2
EPHX1 FN1 LOXL1 SOX3 CCND2 MTA1
GSTM3 SERPINF1 MFAP2 IPO13 GIPC1 FOXE3
UGTB7 HRAS COMMD9 PKNPX1 RGS1 SLC18A2
UGT1A6 TMTC1 ESYT3 TRIM11 RGS2 SOX2
GSTA1 TIMP1 ACYP1 SHH RGS7 BDNF
UGT1A9 OLFM3   GCG   CHMP4B
           
FOXC1 FOXE3 EYA1 LMX1B MAF  
PITX2 GPR161 SIX1 NPHS2 MYB  
DLL4 SOX2 SIX2 WNT7A NPRL3  
HEY2 SMAD4 DACH1 NPS NFE2  
ALX4 PITX2 PAX2 COL4A4 IL4  
MSX2 FOXF2 GDNF PRODH2 ANPEP  
PAX6 FOXH1 SIX5 GPM6A BACH2  
FGF2 SMAD2 PAX1 COK4A3 IRF4  
FLNA HDAC9 TLX1 FOXA2 WHSC1  
CYP1B1 POU5F1 MYOG LDB1 NFATC1  
CXCR4 RSRFR2 PAX3 LRP6    
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3586GLC3A  (2p2-p21),  GLC3B  (1p36.2-p36.1),  or  GLC3C
(14q23).  These  CNVs  did  not  include  any  target  genes
associated with PCG or ASD, nor the predicted functional
partners of the target genes, and none of the genes had a
specific gene function that appeared to be relevant to the
pathogenesis of PCG (Table 3).
These  25  identified  CNVs  might  be  PCG-specific
pathogenic variants or may represent extremely rare benign
variants  that  are  not  associated  with  the  disease.  Further
genetic  strategies  to  validate  these  CNVs  are  needed  to
identify specific gene functions relevant to the pathogenesis
of PCG.
DISCUSSION
In this study, we performed aCGH in a series of 20 individuals
diagnosed  with  PCG  to  discover  novel  copy  number
variations associated with this disease.
First, we chose target genes by expanding the disease
spectrum  of  PCG  to  ASD,  resulting  in  inclusion  of  the
following  target  genes:  CYP1B1,  MYOC,  LTBP2,  PAX6,
PITX2, PITX3, FOXC1, FOXE3, EYA1, LMX1B, and MAF
[11,16-18].  Unlike  PCG,  ASD  is  classified  into  different
subtypes according to the features of malformation affecting
the anterior segment structure, e.g., aniridia, Axenfeld-Rieger
syndrome,  iridogoniodysgenesis,  Peters’  anomaly,  or
posterior embryotoxon. However, some authors have claimed
that PCG also involves abnormal development of Schlemm’s
canal  and  trabecular  meshwork  drainage  structures.
Surprisingly, mutations in the ASD genes sometimes cause
PCG, and PCG genes can also cause ASD [21,22]. In addition,
dysregulation or mutation of a few ocular genes can cause a
range of clinical conditions. For example, PAX6 was first
identified  as  the  gene  for  aniridia,  but  is  now  known  to
Figure 2. Evidence view of predicted functional partners of the CYP1B gene by STRING 8.3. Different line colors represent the types of
evidence used to identify the associations.
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3588underlie a range of other ocular conditions including Peters’
anomaly  and  a  rare  case  of  ASD  [23-25].  PITX2  and
FOXC1 mutations have been found in Peters’ anomaly as well
as  PCG  [26-28].  Peters’  anomaly  is  also  associated  with
mutations in two other genes, CYP1B1 and the FOXC1-related
gene, FOXE3 [29]. Therefore, we hypothesized that PCG may
be considered part of the ASD spectrum; common genetic
pathways may underlie these two disorders.
We explored other genetic mechanisms underlying PCG
by  gene  dosage  analysis,  because  previous  CYP1B1  gene
mutation  studies  have  been  unable  to  explain  the  allelic
heterogeneity  and  pathogenesis  of  PCG  in  all  patients.
Previously,  Kim  et  al.  [10]  performed  direct  sequencing
analysis of all coding exons and flanking intronic regions of
CYP1B1 and MYOC in 85 Korean patients with PCG. These
authors reported that about 70% of Korean PCG patients have
neither CYP1B1 nor MYOC mutations (CYP1B1 mutation
rate, 25.9%; MYOC mutation rate, 2.4%), results consistent
with those reported for Japanese and Chinese patients. Indeed,
12  out  of  22  patients  had  only  one  mutant  allele  in  the
CYP1B1  gene  [10].  In  addition,  the  eye  is  known  to  be
exquisitely  sensitive  to  both  reduced  and  increased  gene
dosage  of  key  developmental  genes.  For  example,  gene
dosage effects have been observed for PAX6 and FOXC1 in
developmental  ocular  anomalies  and  ASD,  respectively
[12-15].
Overall, although we identified 25 CNVs (5 deletions and
20  duplications)  in  12  PCG  patients,  we  were  unable  to
correlate these CNVs with the pathogenesis of PCG using a
reference-based  approach.  The  identified  CNVs  were  not
located in known chromosomal loci for PCG, namely GLC3A
harboring  CYP1B1  (2p21),  GLC3B  (1p36.2-p36.1),  or
GLC3C  (14q23),  and  did  not  include  any  target  genes
associated  with  PCG  and  ASD,  nor  highly  predicted
functional partners of target genes. However, our data suggest
that altered gene dosage may explain the disease pathogenesis
in PCG if these CNVs are PCG-specific pathogenic variants.
Our  study  has  some  limitations.  We  were  unable  to
exclude the existence of pathogenic variants that were too
small to be detected using our platform (<500 bp). Despite the
high genomic resolution of aCGH used in our study, some
genomic regions might not be covered well or may not have
been assessed due to technical difficulties. Furthermore, we
did not perform further studies to determine the gene functions
or expression levels of the CNVs we identified.
In conclusion, this is the first study to comprehensively
investigate gene dosage effects in PCG. We believe that the
preliminary results and the CNV filtering strategy that we used
can broaden our understanding of the genetic mechanisms
underlying PCG.
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